English
Email Chinese
3112018

I-Mab and Genexine Announce China IND Approval for Innovative Immunotherapy A Potential Global First-in-Class Long-Acting IL-7

SHANGHAI, Nov. 02, 2018 – I-MAB Biopharma Co., Ltd. ("I-Mab"), a Shanghai-based biotech company exclusively focused on innovative biologics in immuno-oncology and autoimmune diseases, and Genexine Inc. (KOSDAQ: 095700)...

14102018

First Patient Dosing achieved in Mainland China in a Phase II Multi-regional clinical trial (MRCT)

10th Oct 2018, Shanghai, I-Mab Biopharma (“I-Mab”), a company focusing on innovative biologics in immuno-oncology and immuno-inflammation, today announced that the first patient in mainland China has...

2792018

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs

SHANGHAI, September 26, 2018 — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manuf...

2092018

I-Mab Wins Frost& Sullivan “2018 Best R&D Innovator Award (Biopharma Category)”

I-Mab Biopharma ("I-Mab") announced today that it has been recognized by Forest & Sullivan, the global leading growth consulting company as well as the biggest growth consulting company in China, with...

1082018

I-Mab’s Announces China Clinical Trial Approval of Long-acting hGLP-1 To Treat Type 2 Diabetes

In July, 2018, I-Mab Biopharma (I-Mab) announced that it received clinical trial approval from China National Drug Administration (CNDA) for TJ103 (TG103)...

882018

I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202

I-Mab Biopharma (“I-Mab”), a Shanghai-based biotech company focused on innovative biologics in oncology and autoimmune disease, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segm...

182018

I-Mab Biopharma Announces New CFO

I-Mab Biopharma (“I-Mab”), a Shanghai-based biotech company focusing on innovative biologics in oncology and autoimmune disease, today announced the appointment of Jielun Zhu as Chief Financial Office...

2672018

I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies

I-Mab Biopharma (“I-Mab”), a company focusing on innovative biologics in immuno-oncology and immuno-inflammation, and ABL Bio Corporation (“ABL Bio”), a South Korean biotechnology company...

2962018

I-Mab Successfully Raised US$220 Million in Series C Funding

I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for $220 million USD...

762018

I-Mab Biopharma Opens US Office in Rockville, Maryland

Rockville MD—JUN 2018 — I-Mab Biopharma, announced the opening of its US office in Rockville, Maryland. The grand opening ceremony was honored by the presence of representatives from biotech and pharm...

Home Previous Next End 1/2page  16 10/page To:

Address: Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China, 201210    Tel:86-21-6057 8000     Email:marcom@i-mabbiopharma.com